October 9, 2019 10:19 AM EDT
R&D

Sh­iono­gi cel­e­brates an­tibi­ot­ic win in pneu­mo­nia just ahead of its date with FDA reg­u­la­tors

Amber Tong

Just weeks be­fore Sh­iono­gi is sched­uled to hear back from the FDA on treat­ing com­pli­cat­ed uri­nary tract in­fec­tions with its an­tibi­ot­ic, the Japan­ese phar­ma has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times